

**Danyelza (naxitamab-gqgk)**  
**Effective 01/01/2022**

<b>Plan</b>	<input checked="" type="checkbox"/> MassHealth <input checked="" type="checkbox"/> Commercial/Exchange	<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Benefit</b>	<input type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit (NLX)		
<b>Specialty Limitations</b>	N/A		
<b>Contact Information</b>	<b>Specialty Medications</b>		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	<b>Non-Specialty Medications</b>		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	<b>Medical Specialty Medications (NLX)</b>		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
<b>Exceptions</b>	N/A		

**Overview**

Neuroblastoma is a cancer in which malignant cells form in the neuroblasts in the adrenal glands, neck, chest, or spinal cord.

Danyelza is a GD2-binding monoclonal antibody indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.

**Coverage Guidelines**

Authorization may be reviewed for members new to AllWays Health Partners who are currently receiving treatment with Danyelza excluding when the product is obtained as samples or via manufacturer’s patient assistance programs

**OR**

Authorization may be granted for members when ALL the following criteria are met, and documentation is provided:

1. The member has a diagnosis of high risk, relapsed or refractory neuroblastoma in the bone of bone marrow
2. The member is ≥ 1 year of age
3. The member has demonstrated a partial, minor response, or stable disease with prior therapy
4. The requested medication will be used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) (Leukine [sagramostim])

\*\*Criteria for GM-CSF are located on a separate document.

**Continuation of Therapy**



Reauthorization may be granted when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

### **Limitations**

Initial approvals and reauthorizations will be for 12 months.

### **References**

1. Danyelza [package insert]. New York, NY: Y-mAbs Therapeutics, Inc.; November 2020.

### **Review History**

03/17/2021 – Created and Reviewed at March P&T. Effective 05/01/2021

09/22/2021 – Reviewed at September P&T; removed the GM-CSF medications from appendix (Granix, Neupogen, Nivestym, and Zarxio); Leukine is the only GM-CSF and is now included in the coverage requirements. Effective 01/01/2022

### **Disclaimer**

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.